- Home
- NWBI vs ZLAB Comparison
NWBI vs ZLAB Comparison
Compare NWBI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWBI | ZLAB |
|---|---|---|
| Founded | 1896 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2009 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NWBI | ZLAB |
|---|---|---|
| Price | $15.22 | $25.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $16.43 | ★ $33.48 |
| AVG Volume (30 Days) | ★ 1.2M | 989.1K |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | 16.46 | ★ 38.46 |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $11.47 | N/A |
| Revenue Next Year | $4.86 | $26.74 |
| P/E Ratio | $15.09 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $11.25 | $15.96 |
| 52 Week High | $16.16 | $27.50 |
Technical Indicators
Market Signals| Indicator | NWBI | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 58.32 |
| Support Level | $15.17 | $24.24 |
| Resistance Level | $15.73 | $26.64 |
| Average True Range (ATR) | 0.35 | 1.25 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 27.50 | 88.19 |
Price Performance
Historical ComparisonAbout NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.